Merkel Cell Polyomavirus Infection Induces an Antiviral Innate Immune Response in Human Dermal Fibroblasts

• Published in: Journal of virology 2021-06, Vol.95 (13), p.e0221120
• Main Authors: Krump, Nathan A, Wang, Ranran, Liu, Wei, Yang, June F, Ma, Tongcui, You, Jianxin
• Format: Article
• Language: English
• Subjects: Carcinoma, Merkel Cell - pathology; Cells, Cultured; CRISPR-Cas Systems - genetics; Cytokines - biosynthesis; Cytokines - immunology; Editor's Pick; Fibroblasts - immunology; Fibroblasts - virology; HEK293 Cells; Humans; Immunity, Innate - genetics; Immunity, Innate - immunology; Interferons - biosynthesis; Interferons - immunology; Membrane Proteins - genetics; Merkel cell polyomavirus - growth & development; Merkel cell polyomavirus - immunology; NF-kappa B - genetics; Nuclear Proteins - genetics; Nuclear Proteins - metabolism; Nucleotidyltransferases - genetics; Phosphoproteins - genetics; Phosphoproteins - metabolism; Polyomavirus Infections - immunology; Skin - cytology; Skin - immunology; Spotlight; Tumor Virus Infections - immunology; Virus-Cell Interactions
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/JVI.02211-20

Merkel cell polyomavirus (MCPyV) infects most of the human population asymptomatically, but in rare cases it leads to a highly aggressive skin cancer called Merkel cell carcinoma (MCC). MCC incidence is much higher in aging and immunocompromised populations. The epidemiology of MCC suggests that dysbiosis between the host immune response and the MCPyV infectious cycle could contribute to the development of MCPyV-associated MCC. Insufficient restriction of MCPyV by normal cellular processes, for example, could promote the incidental oncogenic MCPyV integration events and/or entry into the original cell of MCC. Progress toward understanding MCPyV biology has been hindered by its narrow cellular tropism. Our discovery that primary human dermal fibroblasts (HDFs) support MCPyV infection has made it possible to closely model cellular responses to different stages of the infectious cycle. The present study reveals that the onset of MCPyV replication and early gene expression induces an inflammatory cytokine and interferon-stimulated gene (ISG) response. The cGAS-STING pathway, in coordination with NF-κB, mediates induction of this innate immune gene expression program. Further, silencing of cGAS or NF-κB pathway factors led to elevated MCPyV replication. We also discovered that the PYHIN protein IFI16 localizes to MCPyV replication centers but does not contribute to the induction of ISGs. Instead, IFI16 upregulates inflammatory cytokines in response to MCPyV infection by an alternative mechanism. The work described herein establishes a foundation for exploring how changes to the skin microenvironment induced by aging or immunodeficiency might alter the fate of MCPyV and its host cell to encourage carcinogenesis. MCC has a high rate of mortality and an increasing incidence. Immune-checkpoint therapies have improved the prognosis of patients with metastatic MCC. Still, a significant proportion of the patients fail to respond to immune-checkpoint therapies or have a medical need for iatrogenic immune-suppression. A greater understanding of MCPyV biology could inform targeted therapies for MCPyV-associated MCC. Moreover, cellular events preceding MCC oncogenesis remain largely unknown. The present study aims to explore how MCPyV interfaces with innate immunity during its infectious cycle. We describe how MCPyV replication and/or transcription elicit an innate immune response via cGAS-STING, NF-κB, and IFI16. We also explore the effects of this response on MCPyV repl